Singapore Paincare Holdings earnings slump 53.3% in H1 2025

The decline was due to losses from divestments and a joint venture.

Singapore Paincare Holdings reported a 53.5% year-on-year (YoY) drop in earnings for H1 2024 to $0.45m from $0.97m a year ago.

Earnings per share stood at $0.0026.

Revenue for the period rose slightly by 2.8% YoY to $13.73m from $13.36m in H1 2024 mainly due to an increase in revenue from specialist clinics & TCM segments, offset by the decrease in revenue from general practitioners (GP) clinics.

The decrease in revenue from GP clinics is due to the strategic divestment of non-performing clinics, compensated by some relatively new GP clinics, which experienced large revenue increases.

In addition, the group reported a loss of $0.04m from the share of results of a joint venture for Singapore Paincare Capital in H1 2025, an increase from $0.02m in H1 2024.

Follow the link for more news on

Financial Statements

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia